

EN

Back



Guggenheim Upgrades BMY to $62 on FDA's Opdivo Boost

Stock NewsThemesGuggenheim Upgrades BMY to $62 on FDA's Opdivo Boost

Cancer Research

Guggenheim Upgrades BMY to $62 on FDA's Opdivo Boost

Edgen Stock·Dec 18 2025, 14:09

Share to

Share to

Copy link

source:

[1] Guggenheim Sets $62 Target on Bristol-Myers Squibb Company (BMY) After FDA Priority Review (https://finance.yahoo.com/news/guggenheim-set ...)

Related News

Babcock & Wilcox Secures $40M Refinery Contract

Dec 19 2025, 22:38

Babcock & Wilcox Secures $40M Refinery Contract

Babcock & Wilcox announced on December 19, 2025, that it secured a $40 million contract to supply its Wet Gas Scrubbing technology to a Canadian petroleum refinery, major Canadian petroleum refinery.

Tesla Profits Plunge 53% as Politics Cost 1.26M Sales

Dec 19 2025, 22:29

Tesla Profits Plunge 53% as Politics Cost 1.26M Sales

A Yale study finds Elon Musk's political stance cost Tesla 1.26 million car sales, contributing to a profit drop to $7.1 billion in 2024 from $15 billion in 2023.

Mizuho Lifts Tesla Target to $530 on Robotaxi Hopes

Dec 19 2025, 22:27

Mizuho Lifts Tesla Target to $530 on Robotaxi Hopes

On December 16, Mizuho increased its price target for Tesla to $530, citing growing confidence in the automaker's future robotaxi business.